Multilayer UiO-66-NH₂@CS/HA-PNIPAM Nanocomposite for Dual-Responsive Dexamethasone Delivery and Anti-Inflammatory Activity
Downloads
Abstract
Dexamethasone (DEX) is an effective anti-inflammatory drug; however, its therapeutic application can be limited by rapid drug diffusion and insufficient control over the local release profile. In this study, a multifunctional DEX-loaded UiO-66-NH₂@chitosan/hyaluronic acid–poly(N-isopropylacrylamide) (UiO-66-NH₂@CS/HA-PNIPAM) nanocomposite was developed as a dual pH/temperature-responsive drug delivery platform. DEX was incorporated into porous UiO-66-NH₂ nanoparticles, followed by sequential coating with Chitosan (CS)/Hyaluronic Acid (HA) and a thermoresponsive PNIPAM layer. The physicochemical properties, drug encapsulation, swelling behavior, temperature responsiveness, in vitro release, stability, cytocompatibility, and anti-inflammatory activity of the formulations were evaluated. The final F4 formulation exhibited an Encapsulation Efficiency (EE%) of 86.7±2.0% and a particle size of 251.8±9.1 nm, with a Polydispersity Index (PDI) of 0.26±0.03. F4 showed pronounced pH-dependent swelling, increasing from 48.7±3.5% at pH 5.5 to 82.6±4.8% at pH 7.4, while its particle size decreased from 251.8±9.1 nm at 25°C to 211.4±7.1 nm at 37°C, demonstrating temperature-responsive behavior. At pH 7.4 and 37°C, the 24-h cumulative DEX release from F4 was 43.5±2.1%, compared with 78.4±3.1% for the uncoated formulation. The nanocomposite-maintained cell viability above 90% at concentrations up to 100 μg/mL. In an LPS-induced inflammatory model, F4 reduced TNF-α and IL-6 concentrations to 108.6±7.5 and 82.3±6.9 pg/mL, respectively, compared with 286.7±14.8 and 238.5±12.6 pg/mL for the LPS control. The developed UiO-66-NH₂@CS/HA-PNIPAM nanocomposite provided controlled DEX release together with pH/temperature-responsive behavior, acceptable cytocompatibility, and enhanced anti-inflammatory activity, supporting its potential as a multifunctional platform for controlled anti-inflammatory drug delivery.
Keywords
Dexamethasone Chitosan Hyaluronic acid PNIPAM Drug delivery Controlled release Anti-inflammatory activityReferences (30)
- [1] Johnson, D. B., Lopez, M. J., & Kelley, B. (2023). Dexamethasone. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482130/
- [2] Waldron, N. H., Jones, C. A., Gan, T. J., Allen, T. K., & Habib, A. (2013). Impact of perioperative dexamethasone on postoperative analgesia and side-effects: Systematic review and meta-analysis. British Journal of Anaesthesia, 110(2), 191–200. https://doi.org/10.1093/bja/aes431
- [3] Ahmed, M. H., & Hassan, A. (2020). Dexamethasone for the treatment of coronavirus disease (COVID-19): A review. SN Comprehensive Clinical Medicine, 2(12), 2637–2646. https://doi.org/10.1007/s42399-020-00610-8
- [4] Corcoran, T. B., Myles, P. S., Forbes, A. B., Cheng, A. C., Bach, L. A., O’Loughlin, E., ... & Ho, K. M. (2021). Dexamethasone and surgical-site infection. New England Journal of Medicine, 384(18), 1731-1741. https://doi.org/10.1056/NEJMoa2028982
- [5] Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., ... & Recovery Collaborative Group. (2020). Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report. MedRxiv, 2020-06. https://doi.org/10.1101/2020.06.22.20137273
- [6] Baniasad, A., Baei, M. S., & Tala-Tapeh, S. M. (2025). Chitosan-PEGylated niosomes and liposomes as biomacromolecule carriers for Alzheimer’s disease treatment: Galantamine drug delivery carrier. Materials Chemistry and Physics, 352, 132003. https://doi.org/10.1016/j.matchemphys.2025.132003
- [7] Niknejad, K., Sharifzadeh, B. M., & Motallebi, T. T. S. (2018). Synthesis of Metformin Hydrochloride nanoliposomes: Evaluation of physicochemical characteristics and release kinetics. International Journal of Nano Dimension, 9(3), 298-313. https://www.sid.ir/paper/322408/en
- [8] Divya, K., & Jisha, M. S. (2018). Chitosan nanoparticles preparation and applications. Environmental Chemistry Letters, 16(1), 101–112. https://doi.org/10.1007/s10311-017-0670-y
- [9] Mohammed, M. A., Syeda, J. T. M., Wasan, K. M., & Wasan, E. K. (2017). An overview of Chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics, 9(4), 53. https://doi.org/10.3390/pharmaceutics9040053
- [10] Vashisth, V., Lakshmi, Dewangan, H. K., Sharma, N., & Jain, D. (2026). Smart delivery with Chitosan nanoparticles: Current innovations and future pathways. Drug Delivery Letters. https://doi.org/10.2174/0122103031412053260112173343
- [11] Jaaffer, M. D., Hadi, S. J., & Chaloop, A. M. (2026). Hyaluronic acid–targeted PLGA nanoparticles for methotrexate delivery in rheumatoid arthritis. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences, 3(2). https://bionaturajournal.com/repositorio/index.php/bionatura/article/view/254
- [12] Lin, C. W., Hu, W. P., & Su, W. Y. (2026). Hyaluronic acid nanoparticle as drug delivery carrier for the treatment of allergic conjunctivitis. Bio-Medical Materials and Engineering, 37(4-5), 241-252. https://doi.org/10.1177/09592989261474686
- [13] Du, X., Xu, S., Xu, F., Liu, Q., Wang, F., Deng, X., ... & Huang, P. (2026). Tumor-targeted delivery of curcumin via hyaluronic acid-functionalized polymeric nanoparticles: Characterization and mechanistic insights into PI3K/AKT/mTOR signaling. BioNanoScience, 16(8), 532. https://doi.org/10.1007/s12668-026-02771-7
- [14] Hasnawi, D. Al, Masheta, D., & Balakit, A. A. (2026). Rational design, development, and physicochemical characterization of gallic acid-and hyaluronic acid-functionalized selenium nanoparticles. Journal of Nanostructures, 16(4), 4605–4611. https://doi.org/10.22052/JNS.2026.04.010
- [15] Deng, Y. Z., Fu, K. L., Xie, R., Ju, X. J., Wang, W., Liu, Z., & Chu, L. Y. (2026). UCST-type thermo-responsive phase transition behavior of poly (N-isopropylacrylamide) in imidazolium-based ionic liquids. Polymer, 130330. https://doi.org/10.1016/j.polymer.2026.130330
- [16] Siddiqui, A., Touqeer, M., Ritu, F. A., Haider, M. A., Ahmed, A., James-Ocloo, O. S., ... & Huang, D. (2026). A review on thermoresponsive PNIPAM hydrogels for regenerative medicine: From mechanical design to tissue adhesion. Regenerative Biomaterials, 13, rbag045. https://doi.org/10.1093/rb/rbag045
- [17] Umar, A. K., Laomeephol, C., Pannarai, N., Lueantor, C., Thamnium, S., Kaewruethai, T., ... & Luckanagul, J. A. (2026). Mechanistic insights into the self-assembly and cellular uptake of thermoresponsive pNIPAM-grafted hyaluronic acid nanogels. Journal of Pharmaceutical Investigation, 56(5), 1067-1084. https://doi.org/10.1007/s40005-025-00787-x
- [18] Li, X., Bu, X., Huang, J., Li, Y., Wang, L., Miao, H., & Shi, G. (2026). A long-term stable thermochromic smart window of PNIPAM-based hydrogels with excellent water retention and visible light modulation. Journal of Materials Chemistry A, 14(18), 10657–10667. https://doi.org/10.1039/d5ta09352j
- [19] Qiang, X. Q., Wang, X., Du, C., Tang, Y., Wang, H., & Li, N. (2026). Thermoresponsive wettability-switchable PNIPAM composite fibers for enhanced moisture absorption and quick-drying in textiles. Chemical Engineering Journal, 178428. https://doi.org/10.1016/j.cej.2026.178428
- [20] Almazyad, A. F., Haq, N., Alsarra, I. A., Alshehri, S., Alam, P., Imran, M., & Shakeel, F. (2026). Novel drug delivery systems approved by USFDA from 2019 to 2023: A comprehensive review. Current Drug Delivery, 23(4), 396–422. https://doi.org/10.2174/0115672018353367250317063449
- [21] Hrapović, A., Islam, N., Al Bourghli, A., Sezer, A., Kovalenko, B., Lokvančić, H., ... & Uversky, V. N. (2026). Biomaterials in personalized drug delivery: Innovations, challenges, and future directions. PeerJ, 14, e20982. https://doi.org/10.7717/peerj.20982
- [22] Wei, X., Buse, J. B., Chen, H., Desai, T. A., Stevens, M. M., Traverso, G., ... & Gu, Z. (2026). Towards intelligent and miniaturized drug delivery devices. Nature, 651(8107), 897-908. https://doi.org/10.1038/s41586-026-10221-3
- [23] Adepu, S., & Ramakrishna, S. (2021). Controlled drug delivery systems: Current status and future directions. Molecules, 26(19), 5905. https://doi.org/10.3390/molecules26195905
- [24] Park, K. (2014). Controlled drug delivery systems: Past forward and future back. Journal of Controlled Release, 190, 3–8. https://doi.org/10.1016/j.jconrel.2014.03.054
- [25] Razzacki, S. Z., Thwar, P. K., Yang, M., Ugaz, V. M., & Burns, M. A. (2004). Integrated microsystems for controlled drug delivery. Advanced Drug Delivery Reviews, 56(2), 185–198. https://doi.org/10.1016/j.addr.2003.08.012
- [26] Yun, Y. H., Lee, B. K., & Park, K. (2015). Controlled drug delivery: Historical perspective for the next generation. Journal of Controlled Release, 219, 2–7. https://doi.org/10.1016/j.jconrel.2015.10.005
- [27] Nair, S., Ansari, A., Khan, S., Pratap, A., & Mali, S. N. (2026). Anti-inflammatory activity of silver nanoparticles (AgNPs): An updated systematic review from in vivo, and in vitro studies. Inflammopharmacology, 34(4), 2135–2174. https://doi.org/10.1007/s10787-026-02167-9
- [28] Hamed, A. M., Enaili, S. S., I. Mohammed, W., Abouelella, A. M., Mohana, Z. E. E., Monir, D. M., ... & El-Saghier, A. M. (2025). Novel benzenesulfonamide derivatives of 5′-aminospirotriazolotriazine exhibit anti-inflammatory activity by suppressing pro-inflammatory mediators: In vitro and in vivo evaluation using a rat model of carrageenan-induced paw edema. Biomedicines, 13(7), 1732. https://doi.org/10.3390/biomedicines13071732
- [29] Gago, C., Serralheiro, A., & Miguel, M. da G. (2025). Anti-inflammatory activity of thymol and thymol-rich essential oils: Mechanisms, applications, and recent findings. Molecules, 30(11), 2450. https://doi.org/10.3390/molecules30112450
- [30] Tan, X., Chen, P., Xiao, L., Gong, Z., Qin, X., Nie, J., ... & Zhong, S. (2025). Extraction, purification, structural characterization, and anti-inflammatory activity of a polysaccharide from Lespedeza formosa. International Journal of Biological Macromolecules, 300, 140154. https://doi.org/10.1016/j.ijbiomac.2025.140154